Clinical Trial Update: Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects [Phase 1]

View source ↗

Summary

Phase 1 study comparing recombinant factor XIII products produced by two manufacturers in healthy male volunteers to assess comparability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Factor Xiii Deficiency

Drugs mentioned

• Recombinant Factor XIII (Comparator) (Factor XIII, recombinant)
• Recombinant Factor XIII (Novo Nordisk) (Factor XIII, recombinant)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Congenital FXIII Deficiency | Phase 1 | Status: COMPLETED